Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment

This real-world cohort analysis assessed the efficacy of alpelisib and endocrine treatment (ET) combinations in a post-everolimus setting. Thirteen women who started alpelisib and ET at standard doses between 2018 and 2022 for advanced breast cancer (ABC), after undergoing CDK4/6i and everolimus tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Raphael, Ari, Salmon-Divon, Mali, Epstein, Jessica, Zahavi, Tamar, Sonnenblick, Amir, Shachar, Shlomit S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601363/
https://www.ncbi.nlm.nih.gov/pubmed/36292649
http://dx.doi.org/10.3390/genes13101763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601363/
https://www.ncbi.nlm.nih.gov/pubmed/36292649
http://dx.doi.org/10.3390/genes13101763

Ejemplares similares